Financial Performance - For the fiscal year ending December 31, 2025, the company's revenue was RMB 8,174.4 million, a decrease of 20.4% compared to RMB 10,273.3 million in 2024[3]. - Gross profit for the same period was RMB 597.2 million, down 21.9% from RMB 764.4 million in 2024[3]. - The company reported a loss before tax of RMB 328.9 million, which is a 16.0% improvement from a loss of RMB 391.5 million in 2024[3]. - Retail sales totaled RMB 10,341.6 million in 2025, down 18.6% from RMB 12,703.3 million in 2024[6]. - The company reported a net loss of RMB 342.9 million for 2025, an improvement from a net loss of RMB 399.8 million in 2024[99]. - The overall loss before tax for the year was RMB 328,989,000, with a net loss of RMB 342,939,000 after tax expenses of RMB 13,950,000[113]. - The company recorded a net loss of approximately RMB 399.8 million and RMB 342.9 million for the years 2024 and 2025, respectively, with net loss rates of 3.9% and 4.2%[63]. - Adjusted net loss for 2025 was RMB 265.99 million, compared to RMB 327.20 million in 2024, with adjusted net loss rates of 3.25% and 3.18% respectively[67]. Store Operations - The total number of franchise stores managed by the company decreased to 3,639 in 2025 from 4,039 in 2024, while the total number of self-operated stores fell to 8 from 11[5]. - The total number of retail stores increased from 4,386 as of June 30, 2025, to 4,468 as of December 31, 2025, marking a net increase of 82 stores[20]. - The company managed 3,639 franchise stores, accounting for 81.4% of total stores, while self-operated stores remained at 8, representing 0.2%[18]. - The company implemented a strategy to optimize store locations, focusing resources on high-performing stores, which improved operational efficiency[20]. - The company is transitioning to a sustainable store expansion strategy after nearly two years of optimizing its store network[13]. Customer Engagement - The number of members increased to 95,304 in 2025, up from 90,743 in 2024, indicating a growth in customer base[6]. - The total number of WeChat groups reached approximately 32,000, with a total of about 16.9 million fans, and sales through WeChat group purchases exceeded RMB 115.6 million, a year-on-year increase of about 14.0%[26]. - Orders through Douyin group buying channels reached approximately 3.37 million, with retail sales totaling RMB 107 million, representing a year-on-year growth of about 30.9%[26]. - The company’s focus on enhancing customer experience through seasonal product displays and specialized materials has effectively attracted new customers[23]. Financial Position - As of December 31, 2025, the company's net asset value was RMB 2,760.5 million, down from RMB 2,810.3 million in 2024[69]. - Cash and bank deposits increased from RMB 2,340.2 million in 2024 to RMB 2,888.3 million in 2025, including unrestricted cash of RMB 2,037.3 million[70]. - The company’s total assets as of December 31, 2025, were RMB 7,603.7 million, a decrease from RMB 7,819.6 million in 2024[100]. - The total liabilities decreased to RMB 4,843.2 million in 2025 from RMB 5,009.3 million in 2024[101]. - The company’s cash and cash equivalents increased to RMB 1,946.4 million in 2025, up from RMB 1,758.3 million in 2024[100]. Strategic Initiatives - The company is focusing on promoting specialty varieties and applying smart agricultural technologies to enhance supply chain efficiency[11]. - The company plans to expand its retail business significantly in 2026, focusing on personalized services and a refined product offering[39]. - A new "fruit + snack" division is being trialed to optimize store models and enhance supply chain efficiency[40]. - The company plans to develop a comprehensive consumption ecosystem by collaborating with beverage and health companies, as well as government agencies[41]. Market Trends - The overall market for fruit consumption in China grew by approximately 2.0% in 2025, reaching 78.3 million tons, driven by strong demand and diverse consumption trends[10]. - The penetration rate of online channels increased to 26.6% in 2025 from 23.6% in 2024, reflecting a shift in consumer purchasing behavior[11]. - The proportion of gift sales in total retail sales increased from approximately 12.4% in 2024 to about 14.0% in 2025 due to upgraded gift box offerings[28]. Cost Management - Sales cost decreased by approximately 20.3% from RMB 9,508.9 million in 2024 to RMB 7,577.2 million in 2025, consistent with the decline in sales of fruits and other food products[51]. - Employee welfare expenses (excluding provisions and severance compensation) decreased by approximately 20.3% from RMB 662.2 million in 2024 to RMB 527.9 million in 2025 due to digital and intelligent system upgrades[35]. - Research and development expenses decreased from RMB 136.4 million in 2024 to RMB 105.2 million in 2025[44]. Future Outlook - The company aims to achieve high-quality development in 2026, focusing on becoming a leader in high-quality and cost-effective fruit, leveraging over 20 years of industry experience[38]. - The company plans to adopt new accounting standards effective January 1, 2026, which may impact financial reporting and disclosures[107]. - The company continues to seek new business development opportunities, although there are currently no specific plans for significant investments or acquisitions[92].

Financial Performance - The company's revenue for the year ended December 31, 2025, was HKD 6,869,865, a decrease of 20.3% from HKD 8,624,272 in 2024[3] - Gross profit for the year was HKD 68,908, compared to a loss of HKD 66,120 in the previous year, indicating a significant recovery[3] - The net profit attributable to the company's owners for the year was HKD 452,763, an increase of 32.4% from HKD 341,981 in 2024[5] - Basic earnings per share from continuing operations was HKD 0.0596, down from HKD 0.0693 in 2024, reflecting a 13.9% decline[4] - The total pre-tax profit from continuing operations for the year ending December 31, 2025, was HKD 592,798, compared to HKD 814,211 in 2024, indicating a decrease of approximately 27.1%[26][27] - The company reported other operating income and other gains and losses of HKD 15,220 for 2025, compared to HKD 57,440 in 2024, reflecting a decrease of approximately 73.5%[26][27] - The company's profit for the year 2025 was approximately HKD 452.76 million, a decrease of 14% from HKD 526.73 million in 2024[48] - The total revenue from sold inventory in 2025 was HKD 6.80 billion, down from HKD 8.69 billion in 2024, indicating a decline of about 21%[47] - The company declared a final dividend of HKD 1.4 cents per share for the year ending December 31, 2025, totaling approximately HKD 106.41 million, pending shareholder approval[47] Assets and Liabilities - Total assets increased to HKD 8,714,735 in 2025, up from HKD 7,842,287 in 2024, representing an increase of 11.1%[6] - The company's cash and cash equivalents decreased to HKD 944,328 from HKD 1,153,789, a decline of 18.1%[6] - The total equity attributable to the owners of the company rose to HKD 4,563,104, an increase of 16.4% from HKD 3,921,706 in 2024[7] - Total liabilities for the natural uranium trading segment rose to HKD 3,838,245 in 2025 from HKD 3,717,209 in 2024, showing a slight increase of about 3.3%[29] - The total assets of the group increased to HKD 8,714,735 in 2025 from HKD 7,842,287 in 2024, marking an increase of approximately 11.1%[28] - The total liabilities as of December 31, 2025, rose by 6% to HKD 4,152 million, primarily due to increased loans from related companies[111] - Current assets increased by 23% to HKD 4,218 million as of December 31, 2025, driven by a temporary rise in receivables from uranium trading[114] - Non-current assets increased by 2% to HKD 4,497 million, mainly due to the appreciation of financial assets measured at fair value[115] Financial Standards and Reporting - The group has considered the examples provided in the disclosure of uncertainties in financial statements and believes that no additional disclosures or changes in presentation are necessary[11] - The new Hong Kong Financial Reporting Standard 18 will come into effect for annual periods beginning on or after January 1, 2027, and is expected to impact the presentation and disclosure of the income statement in future financial reports[13] - The group is evaluating the specific impact of the new Hong Kong Financial Reporting Standard 18 on its consolidated financial statements[13] - The amendments to the classification and measurement of financial instruments under Hong Kong Financial Reporting Standards 9 and 7 are not expected to have a significant impact on the group's financial statements[16] - The group has not applied any new or amended Hong Kong Financial Reporting Standards that have been issued but are not yet effective[12] - The amendments related to contracts relying on natural energy for electricity production clarify the application of "self-use" provisions and are not expected to significantly impact the group's financial statements[17] - The group’s subsidiaries are considering applying the amended Hong Kong Financial Reporting Standard 19 for their specific financial statements[15] - The amendments to the financial reporting standards will allow early application, but the group does not qualify for the reduced disclosure requirements under Hong Kong Financial Reporting Standard 19[15] Market and Production Insights - The group achieved a uranium production of 862 tU in 2025, meeting its annual plan at 100%, with production costs of $37 per lb U3O8 for the Xie mine and $31 per lb U3O8 for the Yi mine[75] - The average spot price for natural uranium in 2025 is projected to be $72.94 per lb U3O8, with fluctuations throughout the year, peaking at $82.00 per lb U3O8 by the end of September[71] - The global nuclear power growth forecast was raised by the IAEA for the fifth consecutive year, predicting an increase to 992 GWe by 2050 under the high scenario, which is 2.6 times the 2024 capacity[64] - In 2025, China's operational nuclear power units numbered 59, with a total installed capacity of 6,225.894 MW, ranking second in the world[68] - The average grade of uranium in the Xie mine is 0.058%, with a resource amount of 4.6 million tons U (GKZ) and a JORC reserve of 1.8 million tons U[76] - The average grade of uranium in the Zhong mine is 0.044%, with a resource amount of 16.1 million tons U (GKZ) and a JORC reserve of 15.7 million tons U[78] - The company reported a significant increase in uranium production, achieving a total output of 1,200 tons of uranium (tU) for the fiscal year 2025, representing a 15% increase compared to the previous year[139] Strategic Initiatives and Future Outlook - The company plans to enhance supply chain management and optimize procurement to control costs and mitigate risks associated with production in Kazakhstan[92] - The company plans to continue focusing on acquiring competitive low-cost overseas uranium resource projects as its main investment direction[121] - The company has set a revenue guidance of HK$500 million for the next fiscal year, projecting a 10% growth driven by increased production and market expansion efforts[142] - The company is exploring partnerships with international firms to enhance its technological capabilities and expand its operational footprint[142] - The board has approved a budget of HK$100 million for research and development in sustainable mining practices over the next three years[141] - Future outlook remains positive, with analysts projecting a continued rise in uranium prices, potentially increasing revenue by 15% in the next fiscal year[143]

Financial Performance - The reported net profit for the year ending December 31, 2025, is $7,104,000, compared to $2,508,000 for the previous year, representing a significant increase of 184%[2] - Adjusted net profit (non-IFRS measure) for the same period is $9,498,000, up from $7,547,000, reflecting a growth of 25.8%[2] - Total revenue for the year is $109,399,000, an increase from $107,452,000, indicating a growth of 1.8%[3] - Gross profit for the year is $32,635,000, compared to $30,851,000 in the previous year, marking an increase of 5.8%[3] - The company reported a pre-tax profit of $8,502,000, up from $4,214,000, which is an increase of 101.4%[3] - Basic earnings per share for the year is $1.39, compared to $0.49 in the previous year, reflecting a growth of 184%[3] - The company’s total comprehensive income for the year is $7,304,000, compared to $2,362,000 in the previous year, representing an increase of 208%[3] - The company reported a profit attributable to owners of $7,104,000 for 2025, a significant increase from $2,508,000 in 2024, representing a growth of 184.5%[31] - The basic earnings per share for 2025 is $13.93, compared to $4.94 in 2024, reflecting a significant increase of 182.4%[31] Revenue and Regional Performance - North America revenue is projected to decrease from $42,515 thousand in 2024 to $26,425 thousand in 2025, a decline of approximately 37.8%[13] - Europe revenue is expected to increase from $43,317 thousand in 2024 to $50,385 thousand in 2025, a growth of about 16.5%[13] - Asia revenue is forecasted to rise significantly from $13,986 thousand in 2024 to $26,805 thousand in 2025, an increase of approximately 91.5%[13] - Revenue breakdown by region for 2025: North America at $26,425 (24.2%), Europe at $50,385 (46.1%), Asia at $26,805 (24.5%), and Latin America at $5,784 (5.3%)[54] - Customer contract revenue totals $109,399 thousand in 2025, up from $107,452 thousand in 2024, reflecting a growth of about 1.8%[17] Expenses and Cost Management - The company incurred restructuring and redundancy costs of $386,000 in 2025, down from $1,102,000 in 2024, showing a reduction of 65%[2] - Legal expenses amounted to $2,008,000 in 2025, compared to $708,000 in 2024, indicating an increase of 183%[2] - The cost of goods sold for components increased from $63,708 thousand in 2024 to $66,561 thousand in 2025, representing a rise of approximately 4.4%[25] - Research and development expenses decreased from $5,688 thousand in 2024 to $4,215 thousand in 2025, a reduction of about 26.0%[25] - Selling and distribution expenses rose from approximately $7.3 million in 2024 to about $7.8 million in 2025, mainly due to increased employee benefits and professional fees[59] - Administrative expenses were approximately $12 million for both years ending December 31, 2025, and 2024[60] Assets and Liabilities - Total assets increased to $78,409,000 in 2025 from $68,491,000 in 2024, representing a growth of approximately 14.1%[4] - Current liabilities decreased to $32,941,000 in 2025 from $42,808,000 in 2024, a reduction of about 23.2%[4] - Non-current liabilities rose to $602,000 in 2025 from $510,000 in 2024, an increase of approximately 18.0%[5] - Total equity increased significantly to $44,866,000 in 2025 from $25,173,000 in 2024, reflecting an increase of about 78.5%[5] - Cash and cash equivalents amounted to $19,443,000 in 2025, up from $12,000,000 in 2024, indicating a growth of approximately 62.0%[4] - Trade receivables slightly increased to $23,764,000 in 2025 from $23,575,000 in 2024, a marginal rise of about 0.8%[4] - The company reported a net asset value of $34,524,000 in 2025, compared to $14,327,000 in 2024, marking an increase of approximately 141.5%[4] Taxation - The total income tax expense for 2025 is $1,398,000, a decrease of 18.0% from $1,706,000 in 2024[7] - The effective tax rate for 2025 is 16.4%, a decrease from 40.5% in 2024, reflecting improved tax efficiency[7] - The company’s federal tax rate remains stable at 21% for 2025, consistent with 2024[27] Corporate Governance and Management - The company is committed to establishing good corporate governance practices to enhance transparency and accountability to shareholders[100] - The board is actively seeking a suitable candidate to fill the vacancy of the non-executive director position following the resignation of Alain Perrot[101] - The company will continue to review and improve its corporate governance practices to ensure effective leadership and enhance shareholder returns[102] - All directors have confirmed compliance with the standard code of conduct regarding securities trading as of December 31, 2025[103] - The company established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[104] Strategic Initiatives and Future Plans - The company plans to allocate around 70% of the net proceeds from a recent share placement to the development of AIoT technology and personal healthcare management products[47] - The company has established a wholly-owned subsidiary, Orbiva Limited, to further expand its healthcare business[46] - The company aims to enhance operational efficiency and profitability through strategic adjustments and by expanding its product lines with higher profit margins[48] - The company is focusing on cost management, expanding its sales team, and investing in R&D to diversify its business, particularly in home healthcare[51] - The company plans to develop AIoT technology and products, with a budget allocation of HKD 15.95 million (USD 2.05 million) for the first milestone, expected to be utilized by March 2026[92] Shareholder Information - The proposed final dividend for the fiscal year ending December 31, 2025, is $0.66 per share, totaling $3,552,000, pending approval at the upcoming annual general meeting[40] - A final dividend of USD 0.66 per share (approximately HKD 5.19 per share) has been proposed for the year ending December 31, 2025, compared to USD 0.25 per share (approximately HKD 1.93 per share) for the previous year[98] Market and Economic Conditions - The company has not utilized funds originally allocated for R&D and development of OTT products due to the unstable economic environment caused by COVID-19[88] - The company anticipates that the utilization of IPO proceeds will further improve its overall business performance[90] - The group continues to monitor foreign exchange risks and will take prudent measures to minimize currency exchange risks[83] - The group anticipates continued fluctuations in the exchange rates of the Singapore dollar, Chinese yuan, and US dollar[83]

Financial Performance - For the year ending December 31, 2025, the total revenue of Ye Xing Group Holdings Limited was approximately RMB 362.4 million, a decrease of about RMB 14.9 million or approximately 3.9% compared to RMB 377.3 million for the year ending December 31, 2024[2]. - The annual profit and total comprehensive income amounted to approximately RMB 11.1 million, compared to a loss of approximately RMB 21.6 million in 2024[2]. - Basic earnings per share for the year were RMB 2.77, compared to a loss per share of RMB 5.42 in the previous year[4]. - The group reported a profit before tax of RMB 11,218,000 for 2025, recovering from a loss of RMB 21,965,000 in 2024[26]. - The company did not declare or pay any dividends for the years ending December 31, 2025, and 2024[27]. - The company aims to become a leading property management service provider in China, adhering to its core values of friendliness, resilience, innovation, and excellence[41]. Revenue Breakdown - Revenue from property management services accounted for 89.5% of total revenue, while revenue from property developer-related services and value-added services accounted for 1.8% and 8.7%, respectively[2]. - Revenue from property management services for 2025 was RMB 324,285,000, slightly up from RMB 323,809,000 in 2024[19]. - Revenue from value-added services decreased to RMB 31,682,000 in 2025 from RMB 44,130,000 in 2024, representing a decline of approximately 28.2%[19]. - Revenue from property developer-related services decreased by approximately RMB 2.9 million or about 30.9% to approximately RMB 6.5 million[2]. - Revenue from residential properties was RMB 266.1 million, accounting for 82.1% of property management service revenue, while non-residential properties generated RMB 58.2 million, accounting for 17.9%[54]. - In the Beijing region, property management revenue was RMB 101.8 million, representing 31.4% of total revenue, showing stability compared to the previous year[55]. Asset and Liability Management - Non-current assets decreased from RMB 140.6 million in 2024 to RMB 140.6 million in 2025, while current assets increased from RMB 139.9 million to RMB 308.3 million[5]. - Total liabilities increased from RMB 222.3 million in 2024 to RMB 226.6 million in 2025[5]. - The net asset value increased from RMB 214.1 million in 2024 to RMB 224.6 million in 2025[5]. - The group's total assets are approximately RMB 448.9 million as of December 31, 2025, an increase from approximately RMB 422.3 million as of December 31, 2024[72]. - The group's total liabilities are approximately RMB 224.3 million as of December 31, 2025, compared to approximately RMB 208.3 million as of December 31, 2024[72]. Operational Efficiency - The company managed a total gross floor area of approximately 13.3 million square meters across 17 cities in 2025, including 65 residential properties with over 100,000 units[41]. - The company is enhancing service quality and customer value by upgrading service standards and improving customer satisfaction and payment rates[47]. - The company is accelerating technology integration, focusing on smart property management and digital operations to improve efficiency and reduce costs[48]. - The company is committed to strengthening cost control and risk compliance, optimizing project management and organizational structure to improve operational efficiency[50]. Financial Reporting Standards - The group adopted the revised Hong Kong Financial Reporting Standards effective from January 1, 2025, with no significant impact on the financial position and performance for the current and prior years[9]. - The group has not yet applied new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective, which are expected to have no significant impact on the consolidated financial statements[10]. - The financial statements are prepared based on historical cost convention[8]. - The group is currently assessing the detailed impact of the new Hong Kong Financial Reporting Standard No. 18 on its consolidated financial statements[17]. IPO and Capital Management - The net proceeds from the IPO amounted to approximately HKD 129.4 million, which is higher than the estimated amount due to a higher final issue price and lower underwriting costs[84]. - As of December 31, 2025, approximately 65.0% of the IPO proceeds are planned to be used for expanding the geographical footprint and operational scale in China[84]. - Approximately 13.0% of the IPO proceeds are allocated for the development and enhancement of information systems and technological innovation[84]. - The company has adopted a cautious approach to evaluating acquisition targets due to ongoing declines in the real estate industry, resulting in a delay in the planned use of proceeds from the IPO[86]. Governance and Compliance - The company continues to review and monitor its corporate governance practices to ensure compliance with the corporate governance code[97]. - The audit committee reviewed the accounting principles and practices adopted by the group, discussing risk management, internal controls, and financial reporting matters[100]. - The group's auditor confirmed agreement with the financial statements for the year ending December 31, 2025, but did not issue any opinion or conclusion on the announcement[101]. - The board of directors includes both executive and independent non-executive directors, ensuring a diverse governance structure[106].

Financial Performance - Revenue for the year ended December 31, 2025, increased by approximately RMB 129.4 million or about 5.2% to approximately RMB 2,638.5 million compared to RMB 2,509.2 million in 2024[2] - Net profit for 2025 was approximately RMB 105.2 million, a significant recovery from a net loss of approximately RMB 7.9 million in 2024[2] - Gross profit margin for 2025 was approximately 4.0%, compared to a net loss margin of about 0.3% in 2024[3] - Earnings per share for 2025 was RMB 5.92, a turnaround from a loss per share of RMB 0.44 in 2024[3] - The company reported total comprehensive income of RMB 105.1 million for the year, compared to a loss of RMB 7.97 million in 2024[4] - The company reported a profit attributable to shareholders of RMB 105,176 thousand for 2025, a significant recovery from a loss of RMB 7,914 thousand in 2024[23] - The company recorded a net profit of approximately RMB 105.2 million for the year, compared to a net loss of approximately RMB 7.9 million in 2024, resulting in a net profit margin of about 4.0%[78] Dividends and Shareholder Actions - The company has decided not to recommend the payment of a final dividend for the year, consistent with no dividend declared for 2024[3] - The company has decided not to recommend a final dividend for the year ending December 31, 2025, consistent with the previous year[21] - The company executed 23 share repurchase actions, totaling 20,070,000 shares, to enhance shareholder value and support stock price stability[66] - The company repurchased a total of 20,070,000 shares at a total cost of HKD 6,018,040 during the year, with the highest repurchase price being HKD 0.325 and the lowest HKD 0.275[91] Assets and Liabilities - Non-current assets decreased from RMB 381,411 thousand in 2024 to RMB 363,780 thousand in 2025, a decline of approximately 4.3%[5] - Current assets increased from RMB 4,832,485 thousand in 2024 to RMB 5,041,160 thousand in 2025, representing an increase of about 4.3%[5] - Total liabilities rose from RMB 1,614,161 thousand in 2024 to RMB 1,763,731 thousand in 2025, an increase of approximately 9.2%[5] - Net assets increased from RMB 3,512,902 thousand in 2024 to RMB 3,612,512 thousand in 2025, reflecting a growth of about 2.8%[5] - The company’s borrowings increased from RMB 1,418,327 thousand in 2024 to RMB 1,561,569 thousand in 2025, an increase of about 10%[5] - The company’s deferred tax liabilities rose from RMB 25,351 thousand in 2024 to RMB 28,175 thousand in 2025, an increase of approximately 11.5%[5] Revenue Sources and Market Performance - Total revenue for the year ending December 31, 2025, was RMB 2,638,523,000, with external sales contributing RMB 2,638,523,000 and inter-segment sales being RMB 92,525,000[11] - The revenue from the new electronic components segment was RMB 302,071,000, showing a significant contribution to overall sales[11] - Major customers included China Mobile, contributing RMB 1,287,630,000, China Unicom with RMB 697,137,000, and China Telecom with RMB 381,602,000, collectively accounting for over 10% of total revenue[16] - Revenue growth primarily driven by strong performance in key product lines: Flame-retardant soft cables contributed approximately RMB 131.9 million, fiber optic cables and related products contributed approximately RMB 21.8 million, and new electronic components contributed approximately RMB 5.4 million[44] - Sales to the three major telecom operators in China rose by approximately RMB 95.4 million to about RMB 2,366.4 million in 2025, compared to approximately RMB 2,271.0 million in 2024[67] Cost and Expenses - The sales cost for the same period was RMB 2,356,358,000, resulting in a segment performance of RMB 282,165,000[11] - The overall gross profit for 2025 is approximately RMB 282.2 million, a decrease of about 3.9% from RMB 293.6 million in 2024, with a gross profit margin decline of about 1.0 percentage points[44] - Other income decreased from RMB 23,284,000 in 2024 to RMB 8,465,000 in 2025, primarily due to a reduction in interest income and VAT rebates[17] - The company’s administrative expenses decreased from RMB 42,472,000 in 2024 to RMB 40,198,000 in 2025, reflecting cost management efforts[14] - The financing costs reduced from RMB 49,153,000 in 2024 to RMB 41,401,000 in 2025, suggesting improved financial efficiency[14] - Financing costs decreased by approximately RMB 7.8 million or about 15.8% to approximately RMB 41.4 million in 2025, mainly due to a decline in average borrowing rates[76] Market Trends and Future Outlook - The global computing power demand is expected to grow at a compound annual growth rate (CAGR) of over 50% over the next five years, potentially exceeding 16 ZFlops by 2030, with intelligent computing power accounting for over 90%[28] - The construction scale of intelligent computing centers in China is projected to see an additional demand of 10.5GW from 2025 to 2027, indicating a new expansion cycle in the industry[28] - The total scale of the computing power market in China reached RMB 835.1 billion, with a year-on-year growth of over 30%[30] - The group is well-prepared to seize historical opportunities brought by the AI computing era and will continue to expand its market footprint[34] - The group plans to enhance its sales channels and seek growth opportunities in the 5G era, focusing on expanding its market share[54] Employee and Operational Metrics - The group employed a total of 777 full-time employees as of December 31, 2025, an increase from 684 in 2024[85] - The total employee costs rose to RMB 113,910 thousand in 2025, up from RMB 89,213 thousand in 2024, with salaries and other benefits contributing RMB 101,105 thousand[18] Compliance and Governance - The audit committee, consisting of independent non-executive directors, reviewed the group's financial reporting procedures for the year ending December 31, 2025[90] - The annual general meeting is scheduled for May 21, 2026, with a suspension of share transfer registration from May 18 to May 21, 2026[87] - Deloitte has confirmed that the financial figures for the group’s consolidated financial statements for the fiscal year ending December 31, 2025, are in accordance with the board's approval on March 26, 2026[93] - The annual performance announcement will be published on the Hong Kong Stock Exchange and the company's website, containing all information required by the listing rules for the fiscal year ending December 31, 2025[94]

Financial Performance - The company achieved a revenue of RMB 804.4 million for the year ending December 31, 2025, representing a year-on-year growth of 92.7%[3] - The gross profit margin for the reporting period was approximately 44.9%[3] - The adjusted net loss decreased by 51.1% to RMB 89.9 million compared to RMB 183.6 million for the year ending December 31, 2024[5] - The adjusted EBITDA for the reporting period was RMB 50.3 million, marking the first positive EBITDA since the company's establishment[5] - Revenue increased from RMB 417.3 million for the year ending December 31, 2024, to RMB 804.4 million for the year ending December 31, 2025, primarily driven by a significant increase in sales of ophthalmic products and royalties from successful commercialization of 博優景®[36] - Gross profit increased by 60.4% from RMB 225.1 million for the year ending December 31, 2024, to RMB 360.9 million for the year ending December 31, 2025, in line with revenue growth[38] - The company reported a net loss of RMB 158.82 million for 2025, an improvement from a net loss of RMB 268.27 million in 2024[51] - Non-IFRS adjusted EBITDA for 2025 was RMB 50.25 million, compared to a loss of RMB 114.07 million in 2024[51] Product Development and Pipeline - The core product, Youshiying® (fluocinolone acetonide intravitreal implant), continues to play a key role in the company's growth strategy[3] - The product Boiujing® (Aflibercept intravitreal injection solution) received NMPA approval for treating nAMD and DME, marking a significant addition to the company's product portfolio[3] - The company has established a comprehensive ophthalmic drug product line with 43 drug assets, including 27 products in commercialization[6] - The company is focused on developing innovative treatments for dry eye disease, with OT-202 being the first Class I innovative drug for dry eye disease published in a top ophthalmology journal[3] - The candidate drug OT-802 (Pilocarpine) received approval to initiate Phase III clinical trials, targeting the presbyopia indication[20] - OT-703 (Fluocinolone) is set to advance real-world studies in mid-2026, with prior approval for a study involving 195 patients[18][19] - The clinical trial results for OT-202 (Syk/VEGF) were published in the prestigious journal "Ophthalmology," showcasing the company's R&D capabilities[16] - The product pipeline includes a strong focus on ophthalmic diseases, with a clear structure and comprehensive coverage of anterior and posterior eye diseases[17] Production and Capacity - The company completed 27 batches of commercial production at its Suzhou production base during the reporting period, with significant production increases expected in 2026[4] - The company anticipates a major leap in commercial production batches in 2026, including localized production of Youshiying®, which will further reduce overall costs[4] - The production capacity at the Suzhou facility is designed to reach 455 million doses annually, enhancing local production capabilities and reducing overall costs[34] Research and Development - Research and development expenses amounted to RMB 75.1 million, indicating continued investment in the pipeline[15] - Research and development expenses decreased by 34.1% to RMB 75.1 million for the year ending December 31, 2025, from RMB 113.9 million for the year ending December 31, 2024[43] Market and Sales - The company has established coverage in 22,720 hospitals nationwide, including 2,858 tertiary hospitals, with a commercial team exceeding 334 members[26] - Sales of ophthalmic products accounted for RMB 756,175,000 in 2025, up from RMB 384,345,000 in 2024, representing a growth of 96.8%[80] - The revenue from major customer A, which contributed over 10% of total sales, increased to RMB 652,883,000 in 2025 from RMB 305,002,000 in 2024, marking a growth of 114.4%[87] Financial Position - Total current assets decreased to RMB 951.04 million in 2025 from RMB 978.80 million in 2024, while total non-current assets increased to RMB 3,139.92 million from RMB 2,995.01 million[52] - Total liabilities rose to RMB 410.21 million in 2025, up from RMB 200.19 million in 2024, with current liabilities increasing significantly[52] - Cash and cash equivalents decreased to RMB 377.5 million in 2025 from RMB 729.2 million in 2024, primarily due to cash outflows from operating activities and R&D expenses[57] - The company recorded loans of RMB 158.2 million as of December 31, 2025, a significant increase from RMB 16.5 million in 2024, aimed at supplementing working capital[58] Corporate Governance and Compliance - The company is committed to high standards of corporate governance to protect shareholder interests and enhance transparency[97] - Deloitte has verified the financial statements for the year ending December 31, 2025, confirming consistency with the audited financial reports[107] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2025, and recommended it for board approval[108] Future Outlook - The company plans to achieve positive adjusted EBITDA in 2025 and further improvements in 2026, driven by strong business growth and product approvals[29] - The company is focused on accelerating the clinical and registration processes for its pipeline, including OT-502 and OT-101, with key milestones expected between 2026 and 2027[31] - The company aims to deepen collaboration with Alcon to expand market share in the dry eye disease segment and enhance product penetration post-NHI inclusion[32]

Financial Performance - The group's revenue for the year ending December 31, 2025, was approximately RMB 2,649.1 million, a decrease of 5.8% compared to RMB 2,811.6 million for the year ending December 31, 2024[3]. - The net loss for the group for the year ending December 31, 2025, was approximately RMB 983.9 million, compared to a profit of RMB 273.5 million for the year ending December 31, 2024[3]. - The adjusted net profit under non-IFRS was approximately RMB 209.3 million for the year ending December 31, 2025, a decrease of 49.7% from RMB 416.3 million for the year ending December 31, 2024[3]. - The adjusted EBITDA under non-IFRS for the year ending December 31, 2025, was approximately RMB 491.1 million, down 30.6% from RMB 707.3 million for the year ending December 31, 2024[3]. - The total comprehensive loss for the year ending December 31, 2025, amounted to RMB 1,077.3 million, compared to a total comprehensive income of RMB 328.3 million for the year ending December 31, 2024[10]. - The company reported a pre-tax loss of RMB 982,961,000 for the year ended December 31, 2025[22]. - The company reported a net loss attributable to shareholders of RMB 976,146,000 for the year ended December 31, 2025, compared to a profit of RMB 283,099,000 in 2024[41]. - The company reported a significant reduction in reserves from RMB 10,274,237 thousand in 2024 to RMB 9,143,364 thousand in 2025, a decrease of approximately 11%[12]. Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.0418 per share for the year ending December 31, 2025, compared to no dividend for the year ending December 31, 2024[4]. - The proposed final cash dividend for the year ended December 31, 2025, is RMB 100,000,000, equating to RMB 3.70 per share[39]. - A proposed final dividend of approximately RMB 100 million for the year ending December 31, 2025, is set to be distributed, representing about 20% of the adjusted EBITDA[86]. Assets and Liabilities - Total non-current assets decreased from RMB 13,891,865 thousand in 2024 to RMB 12,713,643 thousand in 2025, a decline of approximately 8.5%[11]. - Goodwill decreased significantly from RMB 3,506,618 thousand in 2024 to RMB 2,873,085 thousand in 2025, representing a reduction of about 18%[11]. - Current liabilities decreased from RMB 2,119,451 thousand in 2024 to RMB 1,441,043 thousand in 2025, a decrease of approximately 32%[12]. - Bank borrowings reduced from RMB 1,277,537 thousand in 2024 to RMB 622,890 thousand in 2025, a decrease of about 51%[12]. - Net assets decreased from RMB 10,354,187 thousand in 2024 to RMB 9,198,821 thousand in 2025, a reduction of about 11.1%[12]. - Cash and cash equivalents increased from RMB 546,196 thousand in 2024 to RMB 905,782 thousand in 2025, an increase of approximately 65.5%[11]. - Accounts receivable decreased to RMB 137,791,000 in 2025 from RMB 234,406,000 in 2024, while total receivables and other receivables were RMB 247,876,000[47]. - Total accounts payable increased to RMB 474,183,000 in 2025 from RMB 520,807,000 in 2024, with accounts payable specifically rising to RMB 228,181,000 from RMB 216,965,000[53]. Operational Performance - The group incurred a significant impairment loss of approximately RMB 992.6 million related to goodwill and other intangible assets for the year ending December 31, 2025[9]. - Research and development expenses for the year ending December 31, 2025, were RMB 20.6 million, compared to RMB 24.7 million for the year ending December 31, 2024[9]. - The company reported a gross profit of RMB 886.5 million for the year ending December 31, 2025, down from RMB 1,099.5 million for the year ending December 31, 2024[9]. - Operating costs increased by 2.9% from approximately RMB 1,712.1 million to approximately RMB 1,762.5 million, primarily due to new clinic openings and increased operational costs[105]. - The total employee costs for 2025 were RMB 908,950,000, slightly down from RMB 916,553,000 in 2024[33]. Market and Growth Opportunities - The global IVF market is projected to grow from $3.156 billion in 2025 to $10.466 billion by 2032, representing a compound annual growth rate (CAGR) of 18.7%[59]. - The penetration rate of Assisted Reproductive Services (ARS) in China is only about 10.5% in 2025, significantly lower than Europe (36.5%) and the USA (34.5%)[61]. - The company anticipates that the introduction of fertility subsidies and inclusion of ARS treatments in national health insurance will enhance the accessibility and affordability of these services[63]. - The company is expanding its operational network in California to capitalize on the SB 729 Act, which mandates infertility treatment coverage for large employers[74]. - The company is focusing on optimizing internal operational efficiency, particularly in personnel effectiveness, to significantly reduce labor costs and improve operational efficiency[83]. Strategic Initiatives - The company made a one-time investment of RMB 50,000,000 in Jinjiang Maternal and Child Health Hospital to enhance its capabilities and sustainability in management services[30]. - The company is expanding its presence in Southeast Asia by acquiring the largest assisted reproduction center in Indonesia, which holds a market share of approximately 40%[88]. - The company plans to continue expanding its market presence in high-potential regions in China and Southeast Asia through strategic acquisitions[155][156]. - The company has established a national fertility protection center focused on ovarian tissue cryopreservation, with 47 medical institutions currently performing minimally invasive surgeries[64]. - The company aims to provide a one-stop international medical service for expatriates and residents from Hong Kong, Macau, and Taiwan, focusing on reducing time costs and improving success rates in reproductive health[91]. Compliance and Governance - The company has established an Audit and Risk Management Committee to assist the board in monitoring compliance with applicable laws and regulations[148]. - The company has confirmed compliance with the corporate governance code and standards for the fiscal year ending December 31, 2025[145]. - The financial statements for the year ending December 31, 2025, will be audited and approved by Deloitte, ensuring accuracy in reporting[157].

Financial Performance - For the fiscal year ending December 31, 2025, the revenue was approximately HKD 5,722.7 million, an increase of 87.5% compared to HKD 3,051.9 million in the fiscal year 2024[4] - The gross profit for the fiscal year 2025 was approximately HKD 413.9 million, representing a growth of 132.9% from HKD 177.7 million in the fiscal year 2024[4] - The net profit attributable to the owners of the company for the fiscal year 2025 was HKD 66.6 million, a significant increase from HKD 6.7 million in the fiscal year 2024[4] - The basic earnings per share for the fiscal year 2025 was HKD 0.0631, compared to HKD 0.0063 for the fiscal year 2024[4] - The total comprehensive income for the fiscal year 2025 was HKD 96.3 million, compared to HKD 0.182 million in the fiscal year 2024[6] - The group reported a net profit of HKD 99,916 for fiscal year 2025, compared to HKD 6,222 in fiscal year 2024, marking an increase of approximately 1,505.5%[19] - The company's profit before tax for the fiscal year 2025 was HKD 66,555,000, compared to HKD 6,721,000 in 2024, indicating a significant increase[28] - The total income tax expense for 2025 was HKD 28,864,000, compared to a tax benefit of HKD 2,563,000 in 2024[26] - The deferred tax expense for 2025 was HKD 8,420,000, while it was a tax benefit of HKD 3,126,000 in 2024[26] - The group’s net profit for the fiscal year 2025 was HKD 99.9 million, significantly up from HKD 6.2 million in 2024, attributed to increased product prices and improved cost control measures[60] Revenue Segmentation - For the fiscal year 2025, the total revenue from the digital storage products segment was HKD 4,754,124, a significant increase from HKD 2,078,988 in fiscal year 2024, representing a growth of approximately 128.4%[18] - The total reported segment revenue for fiscal year 2025 was HKD 5,722,667, compared to HKD 3,051,943 in fiscal year 2024, indicating an overall increase of about 87.5%[18] - The total segment profit for digital storage products in fiscal year 2025 was HKD 346,073, up from HKD 92,532 in fiscal year 2024, reflecting a growth of approximately 273.5%[19] - Revenue from external customers in Hong Kong for fiscal year 2025 was HKD 1,528,472, up from HKD 860,659 in fiscal year 2024, representing an increase of about 77.5%[21] - Revenue from external customers in Mainland China for fiscal year 2025 was HKD 4,042,632, compared to HKD 2,141,718 in fiscal year 2024, indicating a growth of approximately 88.8%[21] Assets and Liabilities - Non-current assets decreased from HKD 161,905 thousand in December 2024 to HKD 145,752 thousand in December 2025, representing a decline of approximately 10%[7] - Current assets increased significantly from HKD 1,130,756 thousand in December 2024 to HKD 1,758,954 thousand in December 2025, marking an increase of about 55.5%[7] - Total liabilities rose from HKD 945,643 thousand in December 2024 to HKD 1,468,908 thousand in December 2025, reflecting an increase of approximately 55.5%[7] - The company's net asset value increased from HKD 323,957 thousand in December 2024 to HKD 410,980 thousand in December 2025, a growth of around 27%[8] - The company's cash and cash equivalents rose from HKD 141,697 thousand in December 2024 to HKD 239,879 thousand in December 2025, an increase of approximately 69%[7] - Trade receivables surged from HKD 513,249 thousand in December 2024 to HKD 1,140,461 thousand in December 2025, representing a growth of about 121%[7] - The company's total equity increased from HKD 323,957 thousand in December 2024 to HKD 410,980 thousand in December 2025, indicating a rise of approximately 27%[8] - The company’s non-current liabilities, including convertible bonds, increased from HKD 17,073 thousand in December 2024 to HKD 17,996 thousand in December 2025, a rise of approximately 5.4%[8] - The company’s total assets less current liabilities increased from HKD 347,018 thousand in December 2024 to HKD 435,798 thousand in December 2025, reflecting an increase of about 25.5%[8] Expenses and Costs - The administrative expenses for the fiscal year 2025 were HKD 86.8 million, an increase from HKD 72.3 million in the fiscal year 2024[5] - The financing costs for the fiscal year 2025 were HKD 45.8 million, slightly higher than HKD 45.7 million in the fiscal year 2024[5] - Distribution and selling expenses increased to approximately HKD 152.9 million in 2025, up from HKD 73.3 million in 2024, primarily due to higher salaries and promotional expenses[57] - Administrative expenses rose by approximately HKD 14.5 million to about HKD 86.8 million in 2025, compared to HKD 72.3 million in 2024, mainly driven by salary increases[58] - Research and development expenses for 2025 were approximately HKD 1,968,000, down from HKD 2,981,000 in 2024[25] Trade Receivables and Payables - The company reported a trade receivables impairment reversal of HKD 0.418 million in the fiscal year 2025, compared to an impairment loss of HKD 5.710 million in the fiscal year 2024[5] - The aging analysis of trade receivables shows that amounts overdue by 0 to 30 days rose to HKD 672,418,000 in 2025 from HKD 234,371,000 in 2024, an increase of 187.5%[35] - Trade payables also saw an increase, reaching HKD 334,653,000 in 2025 compared to HKD 216,078,000 in 2024, marking a growth of 55%[36] - The aging analysis of trade payables indicates that amounts overdue by 0 to 30 days increased to HKD 232,757,000 in 2025 from HKD 112,514,000 in 2024, a growth of 106.7%[36] Corporate Governance and Compliance - The group is committed to maintaining high standards of corporate governance and has adopted applicable governance codes to align with the best interests of the group and its shareholders[89] - The audit committee has reviewed and confirmed the accounting principles and standards adopted by the group for the fiscal year 2025[93] - The independent auditor has agreed that the consolidated financial statements for the fiscal year 2025 align with the group's audited financial results[94] - The annual report for fiscal year 2025 will be published on the Hong Kong Stock Exchange website and the company's website by the end of April 2026[96] Future Outlook and Strategy - The group maintains a cautiously optimistic outlook for 2026, focusing on optimizing customer structure and upgrading business layout to enhance market competitiveness[84] - The group plans to enhance its product supply system in the new energy automotive sector to meet the demands of intelligent driving and vehicle networking, aiming to increase market share[86] - The group anticipates a continuous increase in customer orders driven by upgraded industry demand and domestic substitution, providing strong support for core business sales[85] - The group is accelerating its layout in emerging sectors such as new energy vehicles and servers, focusing on high-value customers and high-value-added products for diversified growth[85] - The group expects strong demand in domestic new energy vehicles, servers, and industrial manufacturing, which will further drive domestic sales growth[87] Investments and Acquisitions - The company acquired 18% of Data Star Inc. for a total price of HKD 65,296,000, with HKD 46,800,000 paid in cash and HKD 18,496,000 through the issuance of zero-interest promissory notes[79] - The acquisition was completed on February 9, 2026, resulting in the company holding 90% of the target company's equity[79] - The company issued perpetual subordinated convertible securities and convertible bonds to acquire a property in Hong Kong for HKD 30.0 million[65] - The perpetual subordinated convertible securities have an annual distribution rate of 0.5% and can be converted into 28,570,000 shares, representing 2.66% of the issued shares as of December 31, 2025[66] - The convertible bonds have a term of five years with an annual interest rate of 0.5% and can be converted into 57,140,000 shares, accounting for 5.31% of the issued shares as of December 31, 2025[67] Market Trends - The global semiconductor market is projected to reach USD 791.7 billion in 2025, a 25.6% increase from USD 630.5 billion in 2024, driven by demand for storage and logic chips[41] - The global semiconductor industry is expected to grow by 26% year-on-year in 2026, driven by artificial intelligence and related technologies[80] - The demand for automotive chips is increasing, with the number of chips per electric vehicle rising from 600-800 in traditional vehicles to over 1,000 in electric vehicles[82] - The domestic market for new energy vehicles in China saw production and sales exceeding 16 million units, with new energy vehicles accounting for over 50% of total sales[81] - The company anticipates continued growth in the photovoltaic and energy storage industries, driven by global energy transition trends[82]

Financial Performance - Revenue for the year ended December 31, 2025, was RMB 1,530,672 thousand, a 2.5% increase from RMB 1,500,402 thousand in 2024[3] - Net profit for the year was RMB 32,880 thousand, significantly up from RMB 13,572 thousand in 2024, representing a 142.5% increase[4] - Profit attributable to owners of the company was RMB 33,805 thousand, compared to RMB 16,079 thousand in 2024, marking a 109.5% increase[5] - The total comprehensive income for the year was RMB 27,181 thousand, compared to RMB 16,545 thousand in 2024, an increase of 64.3%[6] - The company reported a profit before tax of RMB 48,126 thousand for 2025, significantly up from RMB 21,172 thousand in 2024, representing a 127.5% increase[23] Revenue Breakdown - Total revenue for the year ending December 31, 2025, reached RMB 1,530,672 thousand, with integrated engineering solutions contributing RMB 1,057,996 thousand, accounting for approximately 69.1% of total revenue[17] - The revenue from sales of goods amounted to RMB 387,959 thousand, representing 25.4% of total revenue, while service revenue contributed RMB 84,717 thousand, or 5.5%[17] - The revenue from the consulting, digitalization, and construction segment was RMB 432,470 thousand, showing a significant contribution to overall performance[21] - The integrated engineering solutions segment saw a revenue increase to RMB 794,199 thousand, reflecting a strong demand for these services[21] Asset and Liability Management - Total assets increased to RMB 2,128,003 thousand from RMB 2,083,635 thousand, reflecting a growth of 2.1%[3] - Total liabilities rose from RMB 1,290,167 thousand in 2024 to RMB 1,303,918 thousand in 2025, an increase of about 1.0%[8] - Equity attributable to owners increased from RMB 791,409 thousand in 2024 to RMB 822,545 thousand in 2025, reflecting a growth of approximately 3.9%[7] - Cash and cash equivalents rose from RMB 166,805 thousand in 2024 to RMB 227,394 thousand in 2025, an increase of about 36.3%[7] Cost Management - Gross profit decreased to RMB 293,271 thousand, resulting in a gross margin of 19.2%, down from 20.1% in the previous year[3] - Research and development expenses were reduced to RMB 45,072 thousand from RMB 53,549 thousand, a decrease of 16.0%[4] - Employee costs, including directors' remuneration, decreased to RMB 368,315 thousand in 2025 from RMB 402,632 thousand in 2024, a decline of 8.5%[35] - Sales and marketing expenses increased to RMB 139,607 thousand in 2025 from RMB 131,851 thousand in 2024, an increase of 5.9%[23] Taxation and Compliance - The company's income tax expenses for 2025 amounted to RMB 8,344,000, compared to RMB 4,316,000 in 2024, representing a 93.5% increase[36] - The effective tax rate for the company's subsidiaries in Hong Kong remained at 16.5% for both 2025 and 2024, with a two-tier profit tax system applicable for certain subsidiaries[37] - The company’s subsidiaries in China benefit from a reduced corporate income tax rate of 15% due to their qualification as high-tech enterprises, with the standard rate being 25%[38] Strategic Initiatives - The company plans to implement the new International Financial Reporting Standard No. 18 starting from January 1, 2027, which is expected to impact the structure and presentation of the consolidated income statement[17] - The company aims to strategically expand into medical devices, medical beauty, and food-grade products by 2026, fostering diversified growth engines[76] - The group is focusing on expanding global business and deepening research and business development in non-pharmaceutical life sciences[66] Market and Industry Trends - The demand for synthetic peptide drugs is expected to increase significantly in 2025, with commercial-scale peptide synthesis systems continuing to gain positive market feedback[67] - The life sciences industry is resilient, covering a wide range of health-related fields, and the company has a deep understanding of its nature and product characteristics[105] - The market demand for more rigorous and cost-effective sterile transfer and containment consumables is expected to increase significantly with the implementation of the National Medical Products Administration's "Sterile Drug Products Appendix" in 2026[100] Digital Transformation and Innovation - The company is implementing a digital transformation to enhance production efficiency and ensure product quality while shortening response times[80] - The company has established a specialized assembly workshop to improve execution efficiency from R&D design to installation and production[82] - The successful launch of a new product for pre-filled syringe inspection has broadened the application scenarios and created new business opportunities[92] Corporate Governance - The company has adopted and committed to implementing the Corporate Governance Code as per the Listing Rules Appendix C1[151] - The Audit Committee has reviewed the company's consolidated financial statements for the year[156] - The group’s auditor has confirmed consistency between the preliminary results announcement and the audited financial statements[157]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 温嶺浙江工量刃具交易中心股份有限公司 Wenling Zhejiang Measuring and Cutting Tools Trading Centre Company Limited* （於中華人民共和國註冊成立的股份有限公司） – 1 – 年度業績 温 嶺 浙 江 工 量 刃 具 交 易 中 心 股 份 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」） 欣 然 公 告 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2025年12月31日止年度的綜 合年度業績，連同上年度的比較數字如下： 綜合損益及其他全面收益表 截 至2025年12月31日止年度 | | | 2025年 | 2024年 | | --- | --- | --- | --- | | | 附 註 | 人民幣千元 | 人民幣千元 | | 收 益 | 3 | 68,973 | 68,814 | | 銷售成本 ...